The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place.
 
Aafke Meerveld-Eggink
No Relationships to Disclose
 
Niels Graafland
No Relationships to Disclose
 
Sofie Wilgenhof
No Relationships to Disclose
 
Johannes V. Van Thienen
Honoraria - MSD (Inst); Novartis (Inst)
 
Michael Grant
No Relationships to Disclose
 
Bernadett Szabados
Honoraria - Merck
Travel, Accommodations, Expenses - Roche/Genentech
 
Yasmin Abu-Ghanem
No Relationships to Disclose
 
Ekaterini Boleti
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics; Neogene Therapeutics
Consulting or Advisory Role - AIMM Therapeutics; AIMM Therapeutics; AIMM Therapeutics; AIMM Therapeutics; AIMM Therapeutics; AIMM Therapeutics; AIMM Therapeutics; AIMM Therapeutics; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celsius Therapeutics; Celsius Therapeutics; Celsius Therapeutics; Celsius Therapeutics; Celsius Therapeutics; Celsius Therapeutics; Celsius Therapeutics; Celsius Therapeutics; Gadeta; Gadeta; Gadeta; Gadeta; Gadeta; Gadeta; Gadeta; Gadeta; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunocore; Immunocore; Immunocore; Immunocore; Immunocore; Immunocore; Immunocore; Ipsen; Ipsen; Ipsen; Ipsen; Ipsen; Ipsen; Ipsen; Ipsen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; MSD; MSD; MSD; MSD; Neogen; Neogen; Neogene; Neogene; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Neon Therapeutics; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Roche
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst)
 
Thomas Powles
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)